Adoptive-transfer therapy of tumors with the tumor-specific primary cytotoxic T cells induced in vitro with the B7.1-transduced MCA205 cell line

Cancer Immunology Immunotherapy

Volumn 47, Issue 5, 1999, Pages 257-264

  Kim, Sun Jung ^a   Sadelain, Michel ^b   Lee, Jeong Soon ^a   Seong, Roh Hyun ^c   Yun, Yeon Sook ^a   Jang, Young Ju ^d   Chung, Hee Yong ^a  

^a Korea Cancer Center Hospital   (South Korea)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Seoul National University   (South Korea)

^d Ajou University   (South Korea)

Author keywords

Adoptive transfer; B7.1; Immunotherapy; Primary cytotoxic T lymphocytes; Tumors

Indexed keywords

B7 ANTIGEN; INTERLEUKIN 2; VIRUS VECTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FIBROSARCOMA; LIMB TUMOR; LUNG TUMOR; MIXED LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS;

ANIMALS; ANTIGENS, CD80; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SARCOMA, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032951063     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050529     Document Type: Article

References (30)

1. 1. Aebersold P, Hyatt C, Jhonson S, Hines K, Korcak L, Sanders M, Lotze M, Topalian S, Yang J, Rosenberg SA (1991) Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst 83:932
2. 2. Bellone M, lezzi G, Manfredi AA, Protti MP, Dellabone P, Casorati G, Rugarli C (1994) In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Eur J Immunol 24:2691
3. 3. Boiardi A, Silvan A, Ruffini PA, Rivoltini L, Parmiani G, Broggi G, Salmaggi A (1994) Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother 39:193
4. 4. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539
5. 5. Economou JS, Belldegrun AS, Glaspy J, Toloza EM, Figlin R, Hobbs J, Meldon N, Kaboo R, Tso CL, Miller A, Lau R, McBride W, Moen RC (1996) In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. J Clin Invest 15:515
6. 6. Evans R, Kamdar SJ, Duffy TM, Krupke DM, Fuller JA, Dudley ME (1995) The therapeutic efficacy of murine antitumor T cells: freshly isolated T cells are more therapeutic than T cells expanded in vitro. Anticancer Res 15:441
7. 7. Gimmi CD, Freeman GJ, Gribben JG (1991) B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete IL-2. Proc Natl Acad Sci USA 88:6575
8. 8. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM (1993) Human T-cell clonal anergy is induced by antigen presentaion in the absence of B7 costimulation. Proc Natl Acad Sci USA 90:6586
9. 9. Gorman C, Padmanabhan R, Howard BH (1983) High efficiency DNA-mediated transformation of primate cell. Science 221:551
10. 10. Greenberg, PD (1991) Adoptive T cell therapy of tumor: mechanism operative in the recognition and elimination of tumor cells. Adv Immunol 49:281
11. 11. Haruta I, Yamaguchi K, Aruga A, Komatsu T, Takasaki K, Hayashi N, Hauyu F (1996) Analytical study of clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma : comparison between LAK cell and CTL therapy. J Immunother 19:218
12. 12. Iezzi G, Protti MP, Rugarli C, Bellone M (1996) B7.1 expression on tumor cells circumvents the need of professional antigen presentation for in vitro propagation of cytotoxic T cell lines. Cancer Res 56:11
13. 13. Li Y, Hellstrom E, Newby SA, Chen L (1996) Costimulation by CD48 and B7-1 induced immunity against poorly immunogenic tumors. J Exp Med 183:639
14. 14. Liu B, Podack ER., Allison JP, Malek TR (1996) Generation of primary CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J Immunol 156:1117
15. 15. Lotze MT, Zeh HJ, Elder EM, Cai Q, Pippin BA, Rosenstein MM, Whiteside TL, Herberman R (1992) Use of T-cell growth factor (interleukin 2, 4, 7, 10, and 12) in the evaluation of T-cell reactivity to melanoma. J Immunother 12:212
16. 16. Marcus SG, Perry-Lalley D, Mule JJ, Rosenberg SA, Yang JC (1994) The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity. J Immunother 15:105
17. 17. Melief CJM (1992) Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 58:143
18. 18. Morgenstern JP, Land HA (1990) A series of mammalian expression vectors and characterization of their expression of a reporter gene in stably and transiently transfected cells. Nucleic Acids Res 18:1068
19. 19. Ohno K, Yoshizawa H, Tsukada H, Takeda T, Yamaguchi Y, Ichikawa K, Maruyama Y, Suzuki Y, Suzuki E, Arakawa M (1996) Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified lymph node cells. J Immunol 156:3875
20. 20. Philips JH, Lanier LL (1986) Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164:814
21. 21. Ramarathinam L, Castle M, Wu Y, Liu Y (1994) T cell co-stimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction recruitment, and effector function of antitumor T cells. J Exp Med 179:1205
22. 22. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis EP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seip CA, Simpson DG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-1 or high dose interleukin-2 alone. N Engl J Med 316:8897
23. 23. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, Merino MJ, Andersen WF (1990) Gene transfer into humans; immunotherapy of patients with advanced melanoma using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323:570
24. 24. Sadelain M, Wang CH, Antoniou M, Grosveld F, Mulligan RC (1995) Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene. Proc Natl Acad Sci USA 92:6728
25. 25. Sule-Suso J, Arienti F, Melani C, Colombo MP, Parmiani GA (1995) B7-1 transfected human melanoma line stimulated proliferation and cytotoxicity of autologous and allogenic lymphocytes. Eur J Immunol 25:2737
26. 26. Walewski J, Paietta E, Dutcher J, Wiernuk PH (1989) Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells. Cancer Res 115:170
27. 27. Wu TC, Huang AYC, Jaffee EM, Levitsk HI, Pardoll DM (1995) A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 182:1415
28. 28. Yang G, Hellstrom KE, Mizuno MT, Chen L (1995) In vitro priming of tumor-reactive cytolytic T lymphocyes by combining IL-10 with B7-CD28 costimulation. J Immunol 155:3897
29. 29.Yannelli JR, Hayatt C, McConnell S, Hines K, Jacknin L, Parker L, Sanders M, Rosenberg SA (1996) Growth of tumor infiltrating lymphocytes from human solid cancer: summary of a 5-year experience. Int J Cancer 65:413
30. 30. Zitvogel L, Tahara H, Cai Q, Storkus WJ, Muller G, Wolf SF, Gatel M, Robbins PD, Lotze MT (1994) Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther 5:1493